Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer

被引：20
|
作者：
Mayer, Erica L. [1 ]
Carey, Lisa A. [2 ]
Burstein, Harold J. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC 27599 USA
来源：
BREAST CANCER RESEARCH | 2007年 / 9卷 / 05期
关键词：
D O I：
10.1186/bcr1755
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Neoadjuvant chemotherapy for breast cancer has a well-established role in the management of patients with locally advanced or early stage disease. Multiple trials have demonstrated superior survival outcomes in individuals achieving a pathologic complete response at the time of definitive surgery, and sophisticated genetic methods may predict which patients will be in this category. Those with less than a pathologic complete response remain at significant risk of recurrent disease, and currently no further standard therapy exists. Ongoing studies of novel agents may lead to improved therapeutic outcomes for this high-risk population.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] CLINICAL IMPLICATION OF MICROSCOPIC RESIDUAL DISEASE AFTER NEOADJUVANT CHEMORADIATION FOR RECTAL CANCER
    Brenner, R.
    Kundel, Y.
    Purim, O.
    Peled, N.
    Ideldvich, E.
    Nisenbaum, B.
    Sulkes, A.
    Fenig, E.
    Brenner, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 110 - 110
  • [32] Effectivness of breast-conserving treatment for minimal residual tumors after neoadjuvant breast cancer therapy
    Pesotsky, R.
    Semiglazov, V.
    Ereschenko, S.
    Bessonov, A.
    Emelyanov, A.
    Tabagua, T.
    Komyahov, A.
    Ivanova, O.
    Zhiltsova, E.
    Nikolaev, K.
    Levchenko, V.
    Zirov, K.
    Krivorotko, P.
    BREAST, 2021, 56 : S61 - S61
  • [33] MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial
    Scheel, John R.
    Kim, Eunhee
    Partridge, Savannah C.
    Lehman, Constance D.
    Rosen, Mark A.
    Bernreuter, Wanda K.
    Pisano, Etta D.
    Marques, Helga S.
    Morris, Elizabeth A.
    Weatherall, Paul T.
    Polin, Sandra M.
    Newstead, Gillian M.
    Esserman, Laura J.
    Schnall, Mitchell D.
    Hylton, Nola M.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 210 (06) : 1376 - 1385
  • [34] Assessment of residual disease and treatment implications post neoadjuvant therapy
    Chang, J. C.
    CANCER RESEARCH, 2017, 77
  • [35] Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
    Luen, S. J.
    Salgado, R.
    Dieci, M. V.
    Vingiani, A.
    Curigliano, G.
    Gould, R. E.
    Castaneda, C.
    D'Alfonso, T.
    Sanchez, J.
    Cheng, E.
    Andreopoulou, E.
    Castillo, M.
    Adams, S.
    Demaria, S.
    Symmans, W. F.
    Michiels, S.
    Loi, S.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 236 - 242
  • [36] Residual microcalcifications after neoadjuvant systemic therapy for early breast cancer: Implications for surgical planning and long-term outcomes
    Allotey, Joel
    Ruparel, Vinita
    Mccallum, Anna
    Somal, Karendeep
    Simpson, Louise
    Gupta, Gaurav
    Lip, Gerald
    Sharma, Ravi
    Masannat, Yazan
    EJSO, 2025, 51 (01):
  • [37] Value of mammographic microcalcifications and MRI-enhanced lesions in the evaluation of residual disease after neoadjuvant therapy for breast cancer
    Zhu, Chao
    Chen, Minglei
    Liu, Yulin
    Li, Pinxiong
    Ye, Weitao
    Ye, Huifen
    Ye, Yunrui
    Liu, Zaiyi
    Liang, Changhong
    Liu, Chunling
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2023, 13 (09) : 5593 - 5604
  • [38] Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
    Steenbruggen, Tessa G.
    van Seijen, Maartje
    Janssen, LiseloreM.
    van Ramshorst, Mette S.
    van Werkhoven, Erik
    Peeters, Marie-Jeanne T. D. F. Vrancken
    Wesseling, Jelle
    Lips, Esther H.
    Sonke, Gabe S.
    CLINICAL CANCER RESEARCH, 2019, 25 (16) : 4985 - 4992
  • [39] Evolution of breast cancer biological subtypes between pre-treatment biopsy and residual disease after neoadjuvant therapy
    Pogoda, K.
    Czopowicz, M.
    Bak, A.
    Najmrocka, D.
    Halasa, P.
    Pawlik, H.
    Olszewski, W.
    Rosinska, M.
    Niwinska, A.
    Sarnowska, E.
    Balata, A.
    Nagadowska, M.
    Gorniak, A.
    Meluch, M.
    Mlodzinska, A.
    Wojda, M.
    Bilska, I.
    Szombara, E.
    Nowecki, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S320 - S321
  • [40] Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer
    Kantor, Olga
    Wong, Stephanie
    Weiss, Anna
    Metzger, Otto
    Mittendorf, Elizabeth A.
    King, Tari A.
    NPJ BREAST CANCER, 2020, 6 (01)
12345